SCHEMBL28107442

SCHEMBL28107442

CC1C=CC=CN1C(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
CTSK P43235 1/20 0.33
RECQL P46063 1/20 0.33
NR1H2 P55055 1/20 0.33
BCHE P06276 1/20 0.33
NPC1 O15118 1/20 0.32
GPR119 Q8TDV5 3/20 0.32
HPGD P15428 1/20 0.32
PREP P48147 1/20 0.31
KDM4E B2RXH2 1/20 0.31
PKM P14618 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28428311 0.81 CHRM2 (0.39) USP2SMN1; SMN2CHRM2CHRM1CHRM3
SCHEMBL19892750 0.80 CHRM2 (0.34) USP2SMN1; SMN2CHRM2CHRM1CHRM3
SCHEMBL30121408 0.80 CHRM2 (0.34) USP2SMN1; SMN2CHRM2CHRM1CHRM3
SCHEMBL28842147 0.79 NR1H2 (0.34) USP2SMN1; SMN2CHRM2CHRM1CHRM3
SCHEMBL27510719 0.76 CTSK (0.33) USP2SMN1; SMN2CHRM2CHRM1CHRM3
SCHEMBL27721708 0.76 PDE4B (0.36) CHRM2CHRM1CHRM3KMT2ANR1H2
SCHEMBL28102330 0.75 LMNA (0.36) SMN1; SMN2CHRM2CHRM1CHRM3MEN1
SCHEMBL4772238 0.73 KMT2A (0.38) MEN1KMT2ACTSKRECQLNR1H2
SCHEMBL23193927 0.72 CHRM2 (0.47) USP2SMN1; SMN2CHRM2CHRM1CHRM3
SCHEMBL27309746 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106117119-A The synthetic method of medicine intermediate 1-tertbutyloxycarbonyl-2-picoline 无锡乾浩生物医药有限公司 2016-11-16 CN claimed
US-20250214964-A1 COMPOUNDS DERIVED FROM 4-AMINO-N-(4-AMINOPHENYL) BENZAMIDE AND ANALOGUES AND USE THEREOF CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) 2025-07-03 US disclosed
CN-106117119-A The synthetic method of medicine intermediate 1-tertbutyloxycarbonyl-2-picoline 无锡乾浩生物医药有限公司 2016-11-16 CN disclosed
CN-106117119-A The synthetic method of medicine intermediate 1-tertbutyloxycarbonyl-2-picoline 无锡乾浩生物医药有限公司 2016-11-16 CN disclosed
CN-106117119-A The synthetic method of medicine intermediate 1-tertbutyloxycarbonyl-2-picoline 无锡乾浩生物医药有限公司 2016-11-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214964-A1 COMPOUNDS DERIVED FROM 4-AMINO-N-(4-AMINOPHENYL) BENZAMIDE AND ANALOGUES AND USE THEREOF ABAT, AADAT, AADAC USP2 4619/4885SMN1; SMN2 3673/4885CHRM2 4477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.